Will Nu Skin Enterprises, Inc. (NUS) Run Out of Steam Soon?

March 13, 2018 - By Louis Casey

Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.05, from 1.12 in 2017Q2. It is negative, as 29 investors sold Nu Skin Enterprises, Inc. shares while 76 reduced holdings. 33 funds opened positions while 79 raised stakes. 38.44 million shares or 4.16% less from 40.11 million shares in 2017Q2 were reported.
Glob X Mgmt Comm Llc holds 0% in Nu Skin Enterprises, Inc. (NYSE:NUS) or 737 shares. Pacad Invest Ltd holds 0.07% or 5,011 shares in its portfolio. Bankshares Of Nova Scotia holds 0.01% or 25,000 shares. Eagle Boston Inv Management Inc invested in 110,923 shares or 0.69% of the stock. Pnc Fincl Svcs Group Inc stated it has 4,224 shares. Meeder Asset Management owns 11,891 shares. Dekabank Deutsche Girozentrale reported 0% stake. Goldman Sachs Grp Inc invested in 1.42 million shares or 0.02% of the stock. Los Angeles Mngmt And Equity Research Inc holds 0.01% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS) for 16,205 shares. Asset Management One Communications Limited reported 49,100 shares or 0.01% of all its holdings. Dimensional Fund Advsrs Lp invested in 0.03% or 1.13M shares. Moreover, Smithfield Trust Com has 0.01% invested in Nu Skin Enterprises, Inc. (NYSE:NUS) for 863 shares. Washington Bank stated it has 0.01% in Nu Skin Enterprises, Inc. (NYSE:NUS). State Street stated it has 1.42M shares. Bluecrest Capital Management reported 4,637 shares stake.

Since October 10, 2017, it had 0 insider purchases, and 6 insider sales for $110.89 million activity. LUND STEVEN sold $1.60M worth of stock. Another trade for 3,000 shares valued at $218,070 was made by DORNY D MATTHEW on Friday, March 2. Another trade for 724 shares valued at $52,751 was sold by Lawrence Mark H. 15,000 shares were sold by Thomas Pisano R., worth $1.08M. 6,933 shares were sold by NAPIERSKI RYAN S, worth $443,712.

The stock of Nu Skin Enterprises, Inc. (NYSE:NUS) hit a new 52-week high and has $79.27 target or 7.00 % above today’s $74.08 share price. The 5 months bullish chart indicates low risk for the $4.02 billion company. The 1-year high was reported on Mar, 13 by Barchart.com. If the $79.27 price target is reached, the company will be worth $281.47M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.01% or $0.01 during the last trading session, reaching $74.08. About 337,841 shares traded. Nu Skin Enterprises, Inc. (NYSE:NUS) has risen 46.60% since March 13, 2017 and is uptrending. It has outperformed by 29.90% the S&P500.

Analysts await Nu Skin Enterprises, Inc. (NYSE:NUS) to report earnings on May, 2. They expect $0.65 EPS, up 27.45 % or $0.14 from last year’s $0.51 per share. NUS’s profit will be $35.28M for 28.49 P/E if the $0.65 EPS becomes a reality. After $1.20 actual EPS reported by Nu Skin Enterprises, Inc. for the previous quarter, Wall Street now forecasts -45.83 % negative EPS growth.

Nu Skin Enterprises, Inc. (NYSE:NUS) Ratings Coverage

Among 9 analysts covering Nu Skin (NYSE:NUS), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Nu Skin had 35 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Nu Skin Enterprises, Inc. (NYSE:NUS) earned “Buy” rating by Citigroup on Thursday, September 15. The rating was maintained by Pivotal Research with “Buy” on Friday, May 5. Sidoti downgraded Nu Skin Enterprises, Inc. (NYSE:NUS) on Wednesday, April 26 to “Neutral” rating. Deutsche Bank maintained the shares of NUS in report on Wednesday, October 7 with “Buy” rating. The stock of Nu Skin Enterprises, Inc. (NYSE:NUS) has “Buy” rating given on Wednesday, September 21 by Citigroup. Stifel Nicolaus maintained it with “Sell” rating and $34 target in Friday, April 29 report. Pivotal Research maintained it with “Buy” rating and $55 target in Friday, April 29 report. Stifel Nicolaus downgraded the stock to “Sell” rating in Wednesday, October 7 report. Stifel Nicolaus maintained the shares of NUS in report on Wednesday, August 2 with “Sell” rating. The stock of Nu Skin Enterprises, Inc. (NYSE:NUS) earned “Buy” rating by Deutsche Bank on Friday, February 16.

More notable recent Nu Skin Enterprises, Inc. (NYSE:NUS) news were published by: Nasdaq.com which released: “Can Robust Strategies Fuel Nu Skin’s (NUS) Q4 Earnings?” on February 12, 2018, also Prnewswire.com with their article: “Nu Skin Enterprises Announces Dividend Increase” published on February 15, 2018, Nasdaq.com published: “Nu Skin Enterprises, Inc. (NUS) Ex-Dividend Date Scheduled for February 23, 2018” on February 22, 2018. More interesting news about Nu Skin Enterprises, Inc. (NYSE:NUS) were released by: Prnewswire.com and their article: “Nu Skin Enterprises To Present At Bank Of America Merrill Lynch 2018 Consumer …” published on March 08, 2018 as well as Prnewswire.com‘s news article titled: “Pre-Market Technical Scan on Personal Products Equities — Herbalife, Kimberly …” with publication date: February 13, 2018.

Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. The company has market cap of $4.02 billion. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC Transformation anti-aging skin care systems; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products. It has a 31.39 P/E ratio. The firm also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.